← Human Trials & Peer-Reviewed Studies
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
Plain-language guide to PMID 9024265 (1997): placebo-controlled randomized controlled trial study of Parathyroid Hormone (PTH 1-84) and Calcitonin in 30 women, osteoporosis and bone density.
Key Facts
- PMID
- 9024265
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Hodsman AB et al. (8 authors)
- DOI
- 10.1210/jcem.82.2.3762
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) and Calcitonin in the context of osteoporosis and bone density in this randomized controlled trial publication.
Why It Was Studied
As PTH also stimulates bone resorption, it is theoretically possible to enhance the anabolic effects of PTH by using a sequential antiresorptive agent in the treatment cycle.
Who Took Part
The study group was 30 women.
PubMed indexes the participants as middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as randomized and placebo-controlled.
The women were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.
The timeline in the abstract includes 42 days.
What Was Measured
Baseline bone mineral density (BMD) at the lumbar spine site revealed t scores of -3.7 +/- 1.2 (+/-SD) for the PTH alone group and -3.0 +/- 1.4 for the PTH + CT groups, who had 2.0 +/- 2.3 and 1.8 +/- 2.4 vertebral fractures, respectively, at entry to the study.
The subject headings attached to it are Alkaline Phosphatase, Bone Density, Calcitonin, Cohort Studies, Femur Neck, Incidence and Lumbar Vertebrae.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Parathyroid Hormone (PTH 1-84) and Calcitonin in 30 women in people with osteoporosis and bone density over 42 days.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1997 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page and the Calcitonin compound page, Osteoporosis and bone density research.
Our Notes on the Compounds
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Calcitonin: A 32-amino-acid hormone that lowers blood calcium; salmon calcitonin (Miacalcin) has been used for Paget disease and osteoporosis.
Related Pages
- Osteoporosis and bone density research
- Parathyroid Hormone (PTH 1-84) in the library
- Calcitonin in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.